Home › Calculator › DNLI Dividend Calculator 2026
DNLI Dividend DRIP Calculator 2026
7.49% YieldHealthcareDenali Therapeutics Inc. · NASDAQ
Price: $26.69 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When DNLI pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your DNLI snowball 📈
$10,000 in DNLI → $661.31M in 10 years · $54,400,145.84/month
About Denali Therapeutics Inc. (DNLI) — Dividend Analysis 2026
Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditions within the United States. The company, initially known as SPR Pharma Inc. until its renaming in March 2015, possesses a robust development pipeline. This includes BIIB122/DNL151, a small molecule inhibitor targeting leucine-rich repeat kinase 2 (LRRK2), currently in Phase 1 and Phase 1b clinical trials for Parkinson's disease. Another candidate, DNL310, is progressing through Phase 1/2 clinical studies for Hunter syndrome. For amyotrophic lateral sclerosis (ALS), DNL343 is in Phase 1 trials, while AR443820/DNL788 has successfully concluded its Phase 1 clinical trial for ALS, multiple sclerosis (MS), and Alzheimer's disease. Furthermore, SAR443122/DNL758 is undergoing Phase 2 clinical trials for cutaneous lupus erythematosus. Denali Therapeutics is engaged in extensive collaborative efforts with a range of partners, including Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene. It also maintains a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG to co-develop antisense therapies specifically for neurodegenerative diseases.
Compare DNLI with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full DNLI DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open DNLI position with:
🌍 DNLI Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold DNLI.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 7.49% | 4.69% | $749 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 6.37% | 3.57% | $637 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 5.99% | 3.19% | $599 / yr |
| 🇬🇧 UK ISA | 0% | 7.49% | 4.69% | $749 / yr |
| 🇬🇧 UK Taxable | 8.75% | 6.83% | 4.03% | $683 / yr |
| 🇨🇦 TFSA | 0% | 7.49% | 4.69% | $749 / yr |
| 🇨🇦 CA Taxable | 25% | 5.62% | 2.82% | $562 / yr |
| 🇦🇺 Super (pension) | 15% | 6.37% | 3.57% | $637 / yr |
| 🇦🇺 AU Taxable | 30% | 5.24% | 2.44% | $524 / yr |
| 🇩🇪 DE Taxable | 26.375% | 5.51% | 2.71% | $551 / yr |
| 🇫🇷 FR Taxable | 30% | 5.24% | 2.44% | $524 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 DNLI Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 DNLI Dividend Payment Schedule
DNLI pays quarterly — 4 times per year. Next ex-div: TBD.
📊 DNLI vs Healthcare Benchmarks
How DNLI compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for DNLI sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ DNLI Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| A-Award | 2026-06-03 | 6,408 | — | — | ||
| A-Award | 2026-06-03 | 19,226 | $19.66 | $378.0K | ||
| A-Award | 2026-06-03 | 6,408 | — | — | ||
| A-Award | 2026-06-03 | 19,226 | $19.66 | $378.0K | ||
| A-Award | 2026-06-03 | 6,408 | — | — | ||
| A-Award | 2026-06-03 | 19,226 | $19.66 | $378.0K | ||
| A-Award | 2026-06-03 | 6,408 | — | — | ||
| A-Award | 2026-06-03 | 19,226 | $19.66 | $378.0K | ||
| A-Award | 2026-06-03 | 6,408 | — | — | ||
| A-Award | 2026-06-03 | 19,226 | $19.66 | $378.0K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst Price Target
Wall Street consensusAnalyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the DNLI dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Denali Therapeutics Inc. (DNLI) is currently trading at $26.69, 66% below its 52-week high. The current dividend yield is 7.49% based on an annual payout of $2.00 per share.
DNLI (Denali Therapeutics Inc.) — 7.49% Dividend Yield Analysis
Denali Therapeutics Inc. (DNLI) is a healthcare stock currently trading at $26.69 with a dividend yield of 7.49%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (7.49%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.
Latest DNLI News
LiveNews aggregated from public sources via Finnhub & RSS. For informational purposes only.